Clinical trials: Glaucoma,Open-Angle
Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension
The goal of this clinical study is to learn how effective and safe is a single administration of PA5346 Ocular Implant for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT06964061
- Testing
- PA5436 Ocular Implant, 115mcg
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- PolyActiva Pty Ltd
Glaucoma, Ocular Hypertension
A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)
Evaluate the effectiveness of dorzolamide-timolol (Cosopt®) as first line therapy in reducing intraocular pressure in patients with untreated Open angle glaucoma (OAG) or Ocular hypertension (OH).
- Trial name
- NCT00546286
- Testing
- dorzolamide hydrochloride (+) timolol maleate, Comparator: dorzolamide HCl/timolol maleate + prostaglandin
- Volunteers
- 170 people
- Sponsor
- Merck Sharp & Dohme LLC
Glaucoma, Ocular Hypertension
Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT
The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs.
- Trial name
- NCT00767494
- Testing
- Travoprost/Brinzolamide fixed combination, Azopt, Travatan
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination (Trav/Brinz) administered twice daily as compared to each of its marketed components (TRAVATAN Z® solution and AZOPT® suspension) and to the…
- Trial name
- NCT02140060
- Testing
- Dose Level A / Brinzolamide 1% ophthalmic suspension, Dose Level B / Brinzolamide 1% ophthalmic suspension, Dose Level C / Brinzolamide 1% ophthalmic suspension
- Volunteers
- 327 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%
The purpose of this study was to evaluate the safety and efficacy of a new ophthalmic suspension (Brinz/Brim) in lowering intraocular pressure (IOP) relative to its individual active components in subjects with open-angle…
- Trial name
- NCT01297920
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 1,062 people
- Sponsor
- Alcon Research
Open Angle Glaucoma or Ocular Hypertension
DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.
- Trial name
- NCT01343082
- Testing
- DE-111 ophthalmic solution
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Open Angle Glaucoma, Ocular Hypertension
Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure
The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with travoprost 0.004% / timolol 0.5% compared to beta-blocker monotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02003391
- Testing
- Beta-blocker monotherapy, Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
- Volunteers
- 157 people
- Sponsor
- Alcon Research
Primary Open-angle Glaucoma
Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost
This study evaluates the efficacy and tolerability of a new formulation of latanoprost without Benzalkonium Chloride (BAK-free).
- Trial name
- NCT03331770
- Testing
- Latanoprost Ophthalmic Product
- Where
- Argentina
- Volunteers
- 103 people
- Sponsor
- Laboratorios Poen
Glaucoma, Open-Angle, Ocular Hypertension
Clinical Study Comparing Two Models of a Travoprost Intraocular Implant
Phase III study to compare the safety and efficacy of intraocular implants containing Travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (Timolol) in reducing elevated intraocular pressure…
- Trial name
- NCT03868124
- Testing
- G2-TR intraocular implant containing travoprost
- Where
- United States
- Volunteers
- 560 people
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma
Hydrus® Microstent New Enrollment Post-Approval Study
The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation.
- Trial name
- CONFIRM (NCT04553523)
- Testing
- Hydrus Microstent, Cataract surgery, Monofocal IOL
- Where
- 22 sites in United States
- Volunteers
- 545 people
- Sponsor
- Alcon Research
Open Angle Glaucoma
A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction
The purpose of this study is to compare the safety and efficacy of goniotomy performed with a novel ophthalmic knife compared to trabecular bypass stent implantation in mild to moderate glaucoma subjects who are also undergoing…
- Trial name
- NCT02784249
- Testing
- Goniotomy, Trabecular Micro-Bypass Stent, Cataract Extraction
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- New World Medical, Inc.
Glaucoma,Open-Angle, Ocular Hypertension
Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®
The primary objective is to evaluate the Intraocular pressure reducing effect of Xalatan over 3 months. The secondary objective is to study the other efficacy parameters during treatment for 3 months
- Trial name
- NCT00486252
- Testing
- Observational
- Volunteers
- 996 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Hypertension, Ocular
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT03657797
- Testing
- NCX 470, Latanoprost 0.005%
- Where
- United States
- Volunteers
- 656 people
- Sponsor
- Nicox Ophthalmics, Inc.
Open Angle Glaucoma or Ocular Hypertension
A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT
The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular…
- Trial name
- NCT02981446
- Testing
- DE-117, Latanoprost ophthalmic solution
- Where
- Singapore
- Volunteers
- 370 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open Angle Glaucoma, Ocular Hypertension
Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension
This is a multiple-dose study of the IOP-lowering efficacy of Azopt (brinzolamide) 1.0% compared to timolol 0.5% when added to a prostaglandin analogue (PGA) as adjunctive therapy over a 24 hour period in patients with glaucoma…
- Trial name
- NCT00300079
- Testing
- brinzolamide 1.0%
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia
PhXA41 is not inferior to timolol in reducing intra-ocular pressure
- Trial name
- NCT00751062
- Testing
- timolol, PhXA41
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Open Angle Glaucoma of Both Eyes
Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL
The goal of this study is to compare efficacy and safety of Dorzotimol eye drops, 20 mg/mL + 5 mg/mL manufactured by JADRAN-GALENSKI LABORATORIJ d.d.
- Trial name
- NCT05973318
- Testing
- Dorzotimol eye drops, 20 mg/mL + 5 mg/mL, Cosopt eye drops, 20 mg/mL + 5 mg/mL
- Where
- Russia
- Volunteers
- 110 people
- Sponsor
- Jadran Galenski laboratorij d.d.
Primary Open Angle Glaucoma
Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the pharmacokinetics, efficacy and safety of T2345 versus an active comparator.
- Trial name
- NCT01494753
- Testing
- T2345, Prostaglandin
- Volunteers
- 30 people
- Sponsor
- Laboratoires Thea
Open-angle Glaucoma, Ocular Hypertension
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the safety and efficacy of AGN-193408 SR in participants with open-angle glaucoma or…
- Trial name
- NCT04499248
- Testing
- AGN-193408 SR, Lumigan, Lumigan Vehicle
- Where
- 49 sites in United States, Japan
- Volunteers
- 100 people
- Sponsor
- AbbVie
Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)
- Trial name
- TRIO (NCT07400926)
- Testing
- Travoprost
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Glaukos Corporation